No Data
No Data
Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial
Avecho Biotechnology (ASX:AVE) has begun patient recruitment for the Phase III clinical trial of its anti-insomnia medication, the company said in a Tuesday filing with the Australian Securities Excha
Avecho to Push Forward With Phase III Trial of Anti-Insomnia Drug
Avecho Biotechnology (ASX:AVE) said the Australian Therapeutic Goods Administration (TGA) has "not recommended any changes" to the design and submission strategy of the firm's proposed Phase III clini
Avecho Biotechnology Secures Ethics Clearance for Phase Three Insomnia Trial
Avecho Biotechnology (ASX:AVE) secured ethics approval to advance its phase three insomnia trial, according to a filing with the Australian Securities Exchange on Thursday. The study aims to investiga
Stocks of the Hour: Dotz Nano, Immuron, Avecho Biotechnology
To register for Friday's webinar click here.Dotz Nano (ASX:DTZ, OTC:DTZNY), a leading developer of innovative climate and industrial nanotechnologies, today announced the completion of a bench-scale d
Avecho Biotechnology (ASX:AVE) Passes "Crucial" Two-year Stability Milestone for CBD Capsule
Avecho Biotechnology (ASX:AVE) Completes the Development of Proprietary TPM Cannabinoid Gummies
No Data